Paul Auer
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Patterns of co-occurring early life trauma (ELT), unlike cumulative trauma, are understudied as potential stress-related health risks. DNA methylation (DNAm) is a posited mechanism linking socioenvironmental stress and disease pathogenesis. We assess whether ELT patterns differentially affect adult DNAm, both epigenome-wide and specifically stress-related genes (eg, glucocorticoid receptor gene, NR3C1). Data represent a case-cohort of non-Hispanic white participants (N = 2566) from the Sister Study, a cohort of US women (ages: 35-74; enrollment: 2003-2009; N = 50 884). Early life trauma measures included a count score and 4 latent ELT classes: low ELT (referent); sexual and emotional; high betrayal; and high ELT. We evaluated epigenome-wide DNAm, differentially methylated regions (DMRs), pathway enrichment, and NR3C1-specific methylation from whole blood. Twenty-two differentially methylated Cytosine–phosphate–Guanine (CpG) sites were associated with ELT classes and none with ELT score. Furthermore, 108 DMRs were associated with ELT score (n = 5) and ELT classes: sexual and emotional (n = 7), high betrayal (n = 37), and high ELT (n = 61). Cardiovascular signaling and leptin signaling pathways were both associated with high betrayal and high ELT classes. In NR3C1-specific analyses, 11 CpGs were associated with ELT score (n = 3) and specific ELT classes (n = 9). Results suggest that specific patterns of co-occurring trauma may contribute to meaningful variability in peripheral blood DNAm in adulthood.
Year:
2026
PURPOSE Hematopoietic cell transplantation (HCT) is considered the only curative treatment for patients with myelodysplastic syndrome (MDS), with disease relapse (REL) as the major cause of post-HCT failure. We aimed to conduct a comprehensive genomic screening of prognostic biomarkers associated with post-HCT disease relapse. METHODS In this retrospective, cohort study, we analyzed whole-genome sequencing data from 494 non-Hispanic White patients with MDS who received HCT in the Center for International Blood and Marrow Transplant Research network. Genomic prognostic biomarkers were determined by cause-specific Cox regression multivariable models, with additional sensitivity analyses on unrelated transplant subcohorts and different competing outcomes. Their clinical significance on post-HCT risk stratifications was further evaluated via random survival forest models with optimism-bias adjusted bootstrap procedure. RESULTS Ten novel genomic biomarkers associated with relapse were identified, including somatic mutations in two genes ( HNRNPA3 and TENM2 ), one locus ( HSPC324 ) with a burden of rare germline single-nucleotide variants (SNVs), six loci harboring common SNVs, and one region harboring a structural variant (SV). For prognostic performance comparisons, the combined model that included these novel genomic biomarkers showed significant improvement of concordance indices (0.747 [95% CI, 0.705 to 0.786]) for predicting post-HCT disease relapse, compared with 0.547 (95% CI, 0.503 to 0.595) in the baseline model (Revised International Prognostic Scoring System [IPSS-R] + hypomethylating agents + graft-versus-host disease prophylaxis). Especially, the combined model showed superior risk stratifications for low or intermediate IPSS-R MDS patients with divergent post-HCT outcomes. CONCLUSION Our results suggest that SNVs and SVs beyond recurrent somatic mutations and cytogenetic abnormalities may play important roles in determining post-HCT relapse risk stratification in patients with MDS.
Year:
2026
A wealth of research focused on African American populations has connected rs2814778-CC (“Duffy-null”) to decreased neutrophil (neutropenia) and leukocyte counts (leukopenia). Although it has been proposed that this variant is benign, prior studies have shown that the misinterpretation of Duffy-null–associated neutropenia and leukopenia can lead to unnecessary bone marrow biopsies, inequities in cytotoxic and chemotherapeutic treatment courses, underenrollment in clinical trials, and other disparities. To investigate the phenotypic correlates of Duffy-null status, we conducted a phenome-wide association study across >1400 clinical conditions in All of Us, the Vanderbilt University Medical Center’s Biobank, and the Million Veteran Program. This reveals that Duffy-null status is only reproducibly associated with changes in white blood cell count and not with any disease outcomes. Moreover, we find that Duffy-null–associated neutropenia is on average less severe than other neutropenia cases in All of Us. We also show that this genotype is present in considerable frequencies in All of Us populations that are genetically similar to African (68%) and Middle Eastern (14%) 1000 Genomes/Human Genome Diversity Project reference populations as well as those who identify with >1 race (12%), as Pacific Islander (7%), and as Hispanic (5%). Furthermore, we find that race is not an accurate predictor of Duffy-null status or associated benign neutropenia. Our research suggests that broad genetic screening of rs2814778 across all populations could provide a more robust and accurate understanding of white blood cell count and mitigate resulting health disparities.
Year:
2025
PURPOSE Cancer-related cognitive impairment (CRCI) and cancer-related fatigue (CRF) are reported by approximately 75% of patients receiving chemotherapy for breast cancer and both have been linked to inflammation. We sought to test whether an inflammation polygenic risk score (iPRS) might be associated with CRCI and/or CRF. METHODS Using data from the UK Biobank, we developed an iPRS for the INFLA-Score, a composite measure of C-reactive protein, white cell count, platelet count, and neutrophil-lymphocyte ratio. The iPRS was evaluated for association with CRCI and CRF among women with nonmetastatic breast cancer enrolled in two completed multisite clinical trials: URCC08106 and URCC10055. CRCI and CRF were measured before and after standard-of-care chemotherapy using the FACT-Cog and Multidimensional Fatigue Symptom Inventory–Short Form (MFSI-SF), respectively. Linear regression evaluated the change in FACT-Cog and MFSI scores; logistic regression evaluated binary outcomes of any versus no worsening of scores. Analyses were adjusted for patient and treatment factors. We also performed exploratory genome-wide analyses. RESULTS The cohort included 802 women who received chemotherapy (anthracycline-based = 51.8%; previous surgery = 85.0%) at a median age of 55 years (range = 22-81). The iPRS was associated with a significant decrease in MFSI-SF score (β = –3.29 [95% CI, –6.25 to –0.34]; P = .029) and lower odds of decreased MFSI-SF score (odds ratio, 0.66 [95% CI, 0.47 to 0.93]; P = .016) following chemotherapy. This negative relationship was partially explained by a positive correlation of the iPRS with prechemotherapy MFSI-SF score (β = 4.33 [95% CI, 0.23 to 8.43]; P = .038). The iPRS was not associated with a change in FACT-Cog score (β = –1.12; P = .627), but single nucleotide polymorphism rs9365961 was (β = –10.05; P = 1.46 × 10 −8 ). CONCLUSION If validated, the iPRS could identify patients in need of supportive care interventions to reduce CRF.
Year:
2025
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
Year:
2025
Mosaic loss of Y chromosome (mLOY) in blood cells is an age-related somatic mutation, but its relationship with pulmonary health remains undercharacterized. Leveraging mLOY assessment in over 12,000 men, including 5,097 from the COPDGene Study and 7,235 from six additional cohorts in Trans-Omics for Precision Medicine program, we investigated its association with respiratory outcomes and epigenetic aging. Cross-sectionally, mLOY was associated with airflow obstruction with prevalence increasing with age, particularly in men with a former smoking history. Longitudinally, mLOY associated with lung function decline. Notably, mLOY was also associated with greater CT-quantified lung emphysema and faster pace epigenetic aging. Prospectively, in participants with normal lung function at baseline, mLOY was associated with lower future lung function and faster pace of epigenetic aging. These associations remained robust after adjusting for clonal hematopoiesis and telomere length. Collectively, these findings position mLOY as a potential biomarker of respiratory aging and obstructive lung disease. Graphical Abstract
Year:
2025
Background: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively affects survivors. Few risk factors are known beyond the radiation dose and volume of bladder exposed. A polygenic risk score (PRS) could identify susceptible patients. Methods: A PRS was built using genome-wide association results from the Radiogenomics Consortium ( N = 3,988) and then tested in the prospective REQUITE and URWCI studies ( N = 2,034). The primary outcome was time to patient–reported gross [grade ≥2, (≥G2)] hematuria, analyzed using Cox proportional hazards regression. Secondary outcomes were ≥G2 urinary retention and frequency. The PRS was externally validated for clinically diagnosed irradiation cystitis in the UK Biobank ( N = 8,430). A gene-burden test evaluated rare coding variants. Results: A 115-variant PRS was associated with a significantly increased risk of ≥G2 hematuria [hazard ratio (HR) per SD = 1.22; P = 0.009] as well as urinary retention (HR per SD = 1.18; P = 0.016) and frequency (HR per SD = 1.14; P = 0.036). When binarized, men in the upper decile (PRS high ) had a >2-fold increased risk of hematuria after adjusting for clinical risk factors [HR = 2.12; P = 0.002; Harrel’s concordance index = 0.71 (95% confidence interval, 0.65–0.76)]. A similar effect size was seen in the UK Biobank for clinically diagnosed irradiation cystitis [odds ratio (OR) = 2.15; P = 0.026]. The burden test identified BOD1L1 as a putative novel radiosensitivity gene. Conclusions: This PRS identifies susceptible patients and could guide the selection of those needing reoptimized treatment plans that spare the bladder beyond currently recommended constraints. Impact: PRS-guided treatment planning in radiation oncology could lower the incidence of clinically relevant bladder toxicity and reduce the impact of this outcome on prostate cancer survivors.
Year:
2025
Genome-wide association studies (GWAS) have become well-powered to detect loci associated with telomere length. However, no prior work has validated genes nominated by GWAS to examine their role in telomere length regulation. We conducted a multi-ancestry meta-analysis of 211,369 individuals and identified five novel association signals. Enrichment analyses of chromatin state and cell-type heritability suggested that blood/immune cells are the most relevant cell type to examine telomere length association signals. We validated specific GWAS associations by overexpressing KBTBD6 or POP5 and demonstrated that both lengthened telomeres. CRISPR/Cas9 deletion of the predicted causal regions in K562 blood cells reduced expression of these genes, demonstrating that these loci are related to transcriptional regulation of KBTBD6 and POP5 . Our results demonstrate the utility of telomere length GWAS in the identification of telomere length regulation mechanisms and validate KBTBD6 and POP5 as genes affecting telomere length regulation.
Year:
2024
Background: Breast cancer has been associated with monogenic, polygenic, and epidemiologic (clinical, reproductive, and lifestyle) risk factors, but studies evaluating the combined effects of these factors have been limited. Methods: We extended previous work in breast cancer risk modeling, incorporating pathogenic variants (PV) in six breast cancer predisposition genes and a 105-SNP polygenic risk score (PRS), to include an epidemiologic risk score (ERS) in a sample of non-Hispanic White women drawn from prospective cohorts and population-based case–control studies, with 23,518 cases and 22,832 controls, from the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Results: The model predicts 4.4-fold higher risk of breast cancer for postmenopausal women with no predisposition PV and median PRS, but with the highest versus lowest ERS. Overall, women with CHEK2 PVs had >20% lifetime risk of breast cancer. However, 15.6% of women with CHEK2 PVs and a family history of breast cancer, and 45.1% of women with CHEK2 PVs but without a family history of breast cancer, had low ( CHEK2 PV carriers at the 10th percentile of the joint distribution of ERS and PRS, without a family history of breast cancer, had a predicted lifetime risk similar to the general population. Conclusions: These results illustrate that an ERS, alone and combined with the PRS, can contribute to clinically relevant risk stratification. Impact: Integrating monogenic, polygenic, and epidemiologic risk factors in breast cancer risk prediction models may inform personalized screening and prevention efforts.
Year:
2024
Supplementary Table S1 shows number of cases and controls and distribution by participating studies, age groups, and family history of breast cancer (first-degree relatives) in CARRIERS consortium
Year:
2024
Collaborators (79)
William A. Hall
-
Tomáš Zima
Head of Institute
Charles University and General University Hospital in Prague, First Faculty of Medicine
Hongying Sun
Assistant Professor
University of Rochester Medical Center
Kathleen Claes
Full professor
Ghent University Hospital
Giuseppe Matullo
-
Lisa Wiesmüller
Professor
Ulm University
Christopher A. Haiman
University of Southern California
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Eric Hahnen
-
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Sara Lindström
University of Washington
Maria Rossing
Associate Clinical Professor
Copenhagen University Hospital
Marco Montagna
Istituto Oncologico Veneto
Katherine Nathanson
Professor
University of Pennsylvania
Nicoletta Resta
Full Professor Medical Genetics
University of Bari Aldo Moro
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Maria Piane
Sapienza University of Rome
Laura Raffield
Assistant Professor
University of North Carolina at Chapel Hill
Sara González
Institut Català d'Oncologia
Jing Dong
Medical College of Wisconsin
FEI CHEN
Assistant Professor
University of Southern California
Matthew Conomos
Senior Research Scientist
University of Washington
Katie O'Brien
Staff Scientist
National Institute of Environmental Health Sciences
Robert Kaplan
PROFESSOR
Albert Einstein College of Medicine
Rebecca Keener
Johns Hopkins University
Zongli Xu
Staff Scientist
National Institute of Environmental Health Sciences
April Carson
University of Mississippi Medical Center
Alexandra Martins
INSERM
Dale Sandler
Branch Chief
National Institute of Environmental Health Sciences
Julie R Palmer
Boston University School of Medicine
Alexander E Volk
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Mariarosaria Calvello
European Institute of Oncology
Alison Margaret Dunning
University of Cambridge
anna coppa
Sapienza University of Rome
Allison DePersia
NorthShore University HealthSystem
Brian Marples
Dr. Sidney H. and Barbara L. Sobel Professor in Radiation Oncology
University of Rochester Medical Center
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Florentia Fostira
National Centre for Scientific Research-Demokritos
Paolo Radice
Head of Reserach Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Maria Elena. Martinez
University of California
Marketa Janatova
Assistanf Professor and researcher
Přírodovědecká Fakulta, Univerzita Karlova
Carol Greider
Professor
University of California, Santa Cruz
Joshua Weinstock
Assistant Professor
Emory University
Gareth Evans
The University of Manchester
Esther John
Professor
Stanford University School of Medicine
Weng Khong Lim
Assistant Professor
Duke-NUS Medical School
Barbara Pasini
Associate Professor of Medical Genetics
Università degli Studi di Torino
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Yasminka Jakubek
University of Kentucky
Megan M Shuey
Vanderbilt University Medical Center
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jeffrey Weitzel
Professor and Director
University of Kansas Cancer Center
Harry Ostrer
Professor
Yeshiva University Albert Einstein College of Medicine
Daniel Levy
Director/Branch Chief/Medical Officer
National Heart Lung and Blood Institute
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Helen Meier
Research Assistant Professor
University of Michigan
Karen Mustian
Professor
University of Rochester Medical Center
Christopher Talbot
Professor of Radiotherapy Genetics
University of Leicester
Michelle C. Janelsins
Division Chief and Professor
University of Rochester Medical Center
Alvaro Monteiro
Senior Member - Full Professor
H Lee Moffitt Cancer Center and Research Institute
Juan Manuel Peralta
Assistant Professor of Research
The University of Texas Rio Grande Valley
Corinna Ernst
Hannover Medical School
Allison W Kurian
Professor
Stanford University School of Medicine
Tiziana Rancati
Researcher
Fondazione IRCCS Istituto Nazionale dei Tumori
Ananya Choudhury
The University of Manchester
Edward Messing
Professor
University of Rochester Medical Center
Kathryn Ruddy
Professor
Mayo Clinic
Lidia Feliubadaló
Institut Català d'Oncologia
Koichi Matsuda
University of Tokyo
Catharine West
The University of Manchester
Joanne Ngeow
Head
Nanyang Technological University (NTU)
Zdenek Kleibl
Laboratory of oncogenetics (head)
Charles University, First Faculty of Medicine
Sarah Kerns
Associate Professor
Medical College of Wisconsin
Nicholas Boddicker
Research Associate
Mayo Clinic
Amanda Toland
Ohio State University
Michael Cho
Brigham and Women's Hospital
Laura Cortesi
University of Modena and Reggio Emilia
Make your next move.
Prepare your application
Review drafts before you send them.